Altamira Therapeutics Ltd... (CYTO)
NASDAQ: CYTO
· Real-Time Price · USD
0.30
0.00 (0.00%)
At close: Jan 16, 2025, 10:00 PM
Altamira Therapeutics Balance Sheet Statement
Financials in CHF. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 617.41K | 617.41K | 49.57K | 49.57K | 15.39K | 15.39K | 372.65K | 372.65K | 984.19K | 984.19K | 8.47M | 8.47M |
Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | 2.5M | 2.5M | 192.96K | 192.96K | 194.26K | 194.26K | 195.42K | n/a | 199.1K | 199.1K | 20K | n/a |
Other Long-Term Assets | n/a | n/a | -4.47M | -4.47M | -4.53M | 0.00 | -16.36M | 195.42K | n/a | n/a | 20K | 20K |
Receivables | 74.82K | n/a | 788.05K | 31.81K | 6.53K | 6.53K | 182.17K | 182.17K | 21.75K | 21.75K | 140.27K | n/a |
Inventory | n/a | n/a | 270.5K | 270.5K | 11.64K | 11.64K | 146.37K | 146.37K | 839.22K | 839.22K | 196.41K | 196.41K |
Other Current Assets | 247.09K | 605.75K | 247.09K | 1.38M | 270.18K | 1.74M | 444.03K | 1.23M | 671.34K | 2.25M | n/a | 484.26K |
Total Current Assets | 1.22M | 1.22M | 1.73M | 1.73M | 1.77M | 1.77M | 1.93M | 1.93M | 3.76M | 4.09M | 9.15M | 9.15M |
Property-Plant & Equipment | 80.11K | 80.11K | 387.74K | 387.74K | 445.83K | 445.83K | 505.27K | 505.27K | 564.72K | 564.72K | 23K | 23K |
Goodwill & Intangibles | 3.89M | 3.89M | 3.89M | 3.89M | 3.89M | 3.89M | 15.85M | 15.85M | 14.31M | 14.31M | 14.54M | 14.54M |
Total Long-Term Assets | 6.47M | 6.47M | 4.47M | 4.47M | 4.53M | 4.53M | 16.55M | 16.55M | 15.08M | 15.08M | 14.59M | 14.59M |
Total Assets | 7.69M | 7.69M | 6.2M | 6.2M | 6.3M | 6.3M | 18.48M | 18.48M | 18.84M | 19.17M | 23.73M | 23.73M |
Account Payables | 413.11K | 413.11K | 1.96M | 1.96M | 4.77M | 4.77M | 3.16M | 3.16M | 3.54M | 3.54M | 1.48M | 1.48M |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | 2.13M | 2.13M | 5.87M | 5.87M | 4.7M | 4.7M | n/a | n/a | n/a | n/a |
Other Current Liabilities | 190.61K | 475.8K | n/a | 1.27M | 362.5K | 2.24M | 284.00 | 1.92M | 196.92K | 1.32M | n/a | 1.59M |
Total Current Liabilities | 888.91K | 888.91K | 5.37M | 5.37M | 12.88M | 12.88M | 9.79M | 9.79M | 4.86M | 4.86M | 3.07M | 3.07M |
Long-Term Debt | n/a | n/a | 930.56K | 1.22M | n/a | 343.63K | n/a | 403.01K | n/a | 461.49K | n/a | n/a |
Other Long-Term Liabilities | 346.63K | n/a | 1.44M | 1.44M | 1.39M | 1.39M | 515.17K | 1.54M | 812.04K | 812.04K | 463.59K | n/a |
Total Long-Term Liabilities | 346.63K | n/a | 2.66M | 2.66M | 1.74M | 1.74M | 1.01M | 1.95M | 1.27M | 1.27M | 578.81K | n/a |
Total Liabilities | 1.24M | 888.91K | 8.03M | 8.03M | 14.62M | 14.62M | 10.8M | 11.74M | 6.13M | 6.13M | 3.65M | 3.07M |
Total Debt | 99.66K | n/a | 3.47M | 3.35M | 6.33M | 6.21M | 5.22M | 5.1M | 575.74K | 461.49K | n/a | n/a |
Common Stock | 2.65K | 2.65K | 1.59M | 1.59M | 236.01K | 236.01K | 170.64K | 170.64K | 149.64K | 149.64K | 136.43K | 136.43K |
Retained Earnings | -18.05M | -18.05M | -19.85M | -19.85M | -201.43M | -201.43M | -182.6M | -183.54M | -176.02M | -175.69M | -164.91M | -164.91M |
Comprehensive Income | 177.58K | 4.4M | 871.63K | 871.63K | 258.04K | 258.04K | -1.41K | -1.41K | 62.07K | 62.07K | 19.38K | 19.37K |
Shareholders Equity | 6.46M | 6.46M | -1.82M | -1.82M | -8.31M | -8.31M | 7.68M | 6.74M | 12.7M | 13.04M | 20.09M | 20.09M |
Total Investments | 2.5M | 2.5M | 192.96K | 192.96K | 194.26K | 194.26K | 195.42K | n/a | 199.1K | 199.1K | 20K | n/a |